Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Myeloma Master Panel (R2-ISS & Frailty)

This master calculator synthesizes the two critical pillars of Multiple Myeloma decision-making: Disease Biology and Patient Physiology.

Evidence-based context for fast calculator use

Purpose:
Integrates Disease Biology (R2-ISS) and Patient Fitness (IMWG) for treatment selection.
Population:
patients whose clinical question requires the component models displayed in the combined panel
Factors:
Beta-2 Microglobulin, Albumin, LDH Level, High Risk Cytogenetics, 1q Gain or Amplification, Age, Katz ADL, Lawton IADL
Reference:
D'Agostino M, Cairns DA, Lahuerta JJ, et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol. 2022;40(29):3406-3418.
HomeMyeloma Master Panel (R2-ISS & Frailty)
Pin your most used calculators here by clicking the star in the dropdown.

Myeloma Master Panel (R2-ISS & Frailty)

Clinical Context & Background

This master calculator synthesizes the two critical pillars of Multiple Myeloma decision-making: Disease Biology and Patient Physiology.
1. Disease Biology: R2-ISS (2022)
The Second Revision of the International Staging System is the current standard for prognostic stratification. It improves upon the R-ISS by incorporating 1q gain/amplification as an independent risk factor.
Formula: ISS Stage (0-1.5 pts) + LDH (1 pt) + High Risk Cytogenetics (1 pt) + 1q Gain (0.5 pts).
Max Score: 5 points.
2. Patient Physiology: IMWG Frailty Score
Determines "biological age" to guide dose intensity. It assesses functional status (ADL, IADL), Comorbidities (CCI), and Age.
Fit: Candidate for full-dose induction (e.g., Quadruplets) and ASCT.
Intermediate: Candidate for standard Triplets; ASCT requires careful evaluation.
Frail: Candidate for "Lite" regimens (e.g., DRd) or dose-attenuated Triplets.
Clinical Synthesis:
The tool cross-references these scores to suggest a treatment strategy (e.g., aggressive curative intent vs. disease control with toxicity minimization).
Primary Source EvidenceD'Agostino M, Cairns DA, Lahuerta JJ, et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol. 2022;40(29):3406-3418.
Formula Logic
Parallel R2-ISS disease-risk and IMWG frailty calculations; component results remain separate and are not averaged.

Reference Data

Score SystemCategory / StageClinical Implication
R2-ISSStage I (0 pts)Low Risk (Median OS: NR)
R2-ISSStage II (0.5 - 1.0 pts)Low-Intermediate (Median OS: ~109 mo)
R2-ISSStage III (1.5 - 2.5 pts)Intermediate-High (Median OS: ~82 mo)
R2-ISSStage IV (3.0 - 5.0 pts)High Risk (Median OS: ~42 mo)
IMWG FrailtyFit (Score 0)Full Dose Induction + ASCT
IMWG FrailtyIntermediate (Score 1)Full or Modified Dose +/- ASCT
IMWG FrailtyFrail (Score ≥ 2)Attenuated Dose; Generally No ASCT

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Myeloma Master Panel (R2-ISS & Frailty) when integrates Disease Biology (R2-ISS) and Patient Fitness (IMWG) for treatment selection.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning R2-ISS through IMWG Frailty.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Review every component result separately; if models disagree, verify inputs and follow the more cautious disease-specific pathway rather than averaging scores.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • A panel improves comparison but does not make component models interchangeable or create a new validated composite score.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients whose clinical question requires the component models displayed in the combined panel

How to apply this result

For a representative case, verify Beta-2 Microglobulin, Albumin, LDH Level, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Share This Calculator

Share:

Related Tools

Febrile Neutropenia TriagePalliative Survival PredictionLiver & HCC Master Panel

Frequently Asked Questions

When should Myeloma Master Panel (R2-ISS & Frailty) be used?

Use it for patients whose clinical question requires the component models displayed in the combined panel when all required inputs and the intended clinical setting are confirmed.

Can Myeloma Master Panel (R2-ISS & Frailty) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.